cholesterol

Expert Panel Recommends Doctors Abandon Vytorin Cholesterol Drug

Sunday, November 02, 2008 by: David Gutierrez, staff writer
Tags: Vytorin, health news, Natural News

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
CDC issues flu vaccine apology: this year's vaccine doesn't work!
Biologist explains how marijuana causes tumor cells to commit suicide
Depopulation test run? 75% of children who received vaccines in Mexican town now dead or hospitalized
Companies begin planting microchips under employees' skin
BAM! Chipotle goes 100% non-GMO; flatly rejecting the biotech industry and its toxic food ingredients
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
NJ cops bust teenagers shoveling snow without a permit
Russia throws down the gauntlet: energy supply to Europe cut off; petrodollar abandoned as currency war escalates
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
Chemotherapy kills cancer patients faster than no treatment at all
March Against Monsanto explodes globally... World citizens stage massive protests across 38 countries, 428 cities... mainstream media pretends it never happened
Why flu shots are the greatest medical fraud in history
600 strains of an aerosolized thought control vaccine already tested on humans; deployed via air, food and water
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Flu vaccine kills 13 in Italy; death toll rises
The 21 curious questions we're never allowed to ask about vaccines
Vicious attack on Dr. Oz actually waged by biotech mafia; plot to destroy Oz launched after episode on glyphosate toxicity went viral
Whooping cough outbreak at Massachusetts high school affected only vaccinated students

Delicious
(NaturalNews) An expert panel from the American College of Cardiology has recommended that doctors stop prescribing the cholesterol-lowering drugs Zetia and Vytorin and stick with the older, proven class of cholesterol drugs known as statins.

"Our strongest recommendation is that people need to go back to statins," said Dr. Harlan Krumholz of Yale University, speaking on behalf of the panel before the college's Chicago meeting.

Among their reasons for coming to consensus that the drugs should no longer be used, the panelists cited lack of evidence that they lengthen patients' lives and lack of knowledge about potential risks.

"We all believe in the primary responsibility as a physician to do no harm," said panel member Joseph Messer, a Chicago cardiologist. "Since we do not know whether that harm could come from this drug, I think it is incumbent upon us to use it in a very conservative manner."

The panel was convened after Merck and Schering-Plough, which distribute the drugs in a joint venture, released the long-delayed results of a study into their effectiveness known as Enhance. Enhance found no evidence that heart disease patients treated with Vytorin lived any longer or had any fewer cardiovascular events than patients treated with a statin alone.

Vytorin is a combination of the statin Zocor (generic name simvastatin) and the newer cholesterol drug Zetia (generic name ezetimibe).

Because Zetia reduces LDL ("bad") cholesterol by a different mechanism than statins do, doctors enthusiastically embraced the combination Vytorin drug as a way to bring LDL levels much lower than would be possible with Zocor alone. Together, Zetia and Vytorin have pulled in $5 billion per year for manufacturers Merck and Schering-Plough.

Zetia lowers LDL levels by hampering the intestine's ability to absorb dietary cholesterol, while statins accelerate the filtering out of LDL cholesterol from the blood.

Krumholz said that because the effects of statins are well-known, doctors should stick to those drugs instead of the unproven Zetia and Vytorin.

"We know statins are good drugs and we know they reduce risks. We believe in general to get to a $5 billion-a-year drug, there was a lot of premature use of ezetimibe before the statin option had been exhausted," he said.

In contrast to statins, the risks of Zetia and Vytorin are not well-studied or well-known, Krumholz emphasized.

"We do not know. This is a new drug with a novel mechanism - first in class. We do not have outcomes studies," he said

No large-scale studies have ever been conducted into the safety of Zetia and Vytorin, in particular whether they raise the risk of heart attacks and strokes. The first such study is due to be completed in 2012.

The Enhance study and the panel's recommendations should have wider ramifications in the way that doctors approach heart health and new drugs, the panelists said.

The panelists noted that many doctors assumed that just because Zetia and Vytorin lowered LDL cholesterol, they must be improving heart health. But this assumption appears to have been faulty, as the mechanism by which cholesterol is lowered may be just as significant as the size of the cholesterol decrease.

"Drugs are complex compounds with an array of biological effects. Knowing how they affect lipids does not tell us how they affect people," Krumholz said.

Enhance "reminds us to look at the trial endpoint and how (drugs) affect patients and not to just look at the numbers," panelist Rick Nishimura of the Mayo Clinic agreed.

Following the panel's recommendations, shares of Merck fell 15 percent, while shares of Schering-Plough dropped 26 percent.

The two companies had previously been accused of intentionally delaying the release of the Enhance results in order to preserve their profits, and of concealing evidence that Zetia may lead to liver damage.

Sources for this story include: www.reuters.com, www.forbes.com.

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.